Dr. Herbst on the Benefit of Targeting PD-1/PD-L1

Roy S. Herbst, MD, PhD
Published: Tuesday, Feb 04, 2014

Roy S. Herbst, MD, PhD, a professor of medicine at the Yale Cancer Center and chief of medical oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses the unique benefit of targeting the PD-1/PD-L1 pathway in lung cancer.

Herbst says that some older vaccines in lung cancer may have been able to benefit patients if they were used with an immune checkpoint inhibitor or an adoptive T cell therapy.

The PD-1/PD-L1 is a prevalent pathway involved in immune regulation. Researchers are seeing mutations presented at the surface of a tumor cell are activating T cells, which then get checked by natural checkpoints in the body. This block must be relieved.

This inhibition of the PD-1/PD-L1 pathway has shown benefit in other cancers as well as lung cancer, Herbst says.

Roy S. Herbst, MD, PhD, a professor of medicine at the Yale Cancer Center and chief of medical oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses the unique benefit of targeting the PD-1/PD-L1 pathway in lung cancer.

Herbst says that some older vaccines in lung cancer may have been able to benefit patients if they were used with an immune checkpoint inhibitor or an adoptive T cell therapy.

The PD-1/PD-L1 is a prevalent pathway involved in immune regulation. Researchers are seeing mutations presented at the surface of a tumor cell are activating T cells, which then get checked by natural checkpoints in the body. This block must be relieved.

This inhibition of the PD-1/PD-L1 pathway has shown benefit in other cancers as well as lung cancer, Herbst says.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x